Apoptosis, clearance mechanisms, and the development of systemic lupus erythematosus.

被引:34
|
作者
Navratil J.S. [1 ]
Ahearn J.M. [1 ]
机构
[1] University of Pittsburgh School of Medicine, University of Pittsburgh Arthritis Institute, S705 Biomedical Science Tower, 3500 Terrace Street, Pittsburgh, 15261, PA
关键词
Systemic Lupus Erythematosus; Apoptotic Cell; Immune Tolerance; Classical Pathway; Congenital Heart Block;
D O I
10.1007/s11926-001-0018-1
中图分类号
学科分类号
摘要
Cell death by apoptosis is an integral part of many biologic processes, including embryonic development, T- and B-cell selection, the elimination of potentially autoreactive lymphocytes in the periphery, and maintenance of lymphocyte homeostasis through activation-induced cell death. There is also increasing evidence that apoptosis may maintain immune tolerance and that it may be the process that generates the self antigens responsible for the initial development of autoimmunity. This review discusses some of the biochemical steps involved in the apoptotic process, how potentially immunogenic self antigens are generated during apoptosis, and the mechanisms by which the products of apoptosis are cleared and processed to avoid breaking immune tolerance.
引用
收藏
页码:191 / 198
页数:7
相关论文
共 50 条
  • [41] Reproductive and hormonal risk factors for the development of systemic lupus erythematosus.
    Cooper, GS
    Dooley, MA
    Treadwell, EL
    St Clair, EW
    Gilkeson, GS
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S130 - S130
  • [42] Ocular manifestations of systemic lupus erythematosus.
    Libes, J
    Petri, M
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S611 - S611
  • [43] Hormone therapy in systemic lupus erythematosus.
    Domsic R.T.
    Manzi S.
    Current Rheumatology Reports, 2005, 7 (6) : 455 - 456;discussion456
  • [44] Bone health and systemic lupus erythematosus.
    Lee C.
    Ramsey-Goldman R.
    Current Rheumatology Reports, 2005, 7 (6) : 482 - 489
  • [45] Neuropsychiatric involvement in systemic lupus erythematosus.
    Hermosillo-Romo D.
    Brey R.L.
    Current Rheumatology Reports, 2002, 4 (4) : 337 - 344
  • [46] ACR criteria for Systemic Lupus Erythematosus.
    Petri, M
    Singh, V
    Alarcon, GS
    Aranow, C
    Bae, SC
    Buyon, J
    Clarke, A
    Ginzler, E
    Kalunian, K
    Maddison, P
    Manzi, S
    Merrill, J
    Ramsey-Goldman, R
    Sturfelt, G
    Urowitz, M
    van Vollenhoven, R
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S189 - S189
  • [47] Predictors of Panniculitis in Systemic Lupus Erythematosus.
    Odhav, Ashika
    Petri, Michelle
    Fang, Hong
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S600 - S600
  • [48] Methotrexate use in systemic lupus erythematosus.
    Morand, EF
    Kipen, Y
    Littlejohn, GO
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1361 - 1361
  • [49] Physical activity and systemic lupus erythematosus.
    Fitzgerald, SG
    Manzi, S
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 791 - 791
  • [50] Hypogammaglobulinemia in Pediatric Systemic Lupus Erythematosus.
    Lim, Emilina
    Cooper, Megan A.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S957 - S958